A big THANK YOU to all the attendees joining this year’s SFB1160 PPII conference, for all the amazing talks and the lively discussions, we are very happy to have had you all here in Freiburg in presence !
The scientific committee had put together a wonderful 3-day programme that attracted more than 260 participants to listen to and discuss exciting scientific talks.
Thank you all for the exciting talks, the lively discussions and your participation that made the PPII symposium a great success!
Just a couple of impressions:
The programme was accompanied by several seleted short-talks from Kathrin Heim (A02, Thimme/Hofmann group) and Daniel Schnepf with new insights on HBV-specific CD8 T cells and impaired SARS-CoV-2-specific immune responses in aged mice, respectively. Nadine Wössner (B01, Minguet group) on small-molecule inhibitors disrupting a novel interaction site of Lck and the TCR, and Viviane Dettmer-Monaco (A07, Cathomen group) with a pre-clinical proof of concept treatment for FHL-3, Ian Edward Gentle on GM-CSF suppresses LPS induced antioxidant responses through NRF2 downregulation, driving IL-1β ubiquitylation, and secretion; Lukas Amann (Kierdorf group) on Specification of CNS macrophage subsets occurs postnatally in defined niches; Selina Keppler on B cells fueling intestinal inflammation; Julian Staniek (B02, Rizzi group) on Non-apoptotic FAS signaling controls CD40-dependent mTOR activation and balances extrafollicular versus germinal center fate in human B cells; Carmen Gómez-Escolar on Single cell clonal analysis identifies an AID-dependent pathway of plasma cell differentiation and Teresa Fuertes on miR-28 enhances the anti-tumoral effect of ibrutinib inducing a cell cycle arrest transcriptional program in aggressive B lymphomas.